International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-1 doi: 10.5281/zenodo.14211697
Original Research Article
Transversalis Fascia Fixation to Coopers Ligament in Inguinal Hernia Tapp Repair: A Prospective Single-Center Cohort Study
Published
Jan. 26, 2025
Abstract

Background:Seroma development, also referred to as "pseudorecurrence," is a frequent postoperative issue following TAPP treatment of inguinal hernias, menace to operating surgeon answering questions to patients either be a self-limiting, asymptomatic event or a painful, long-term issue. In order to better understand incident of postoperative seroma following laparoscopic transabdominal preperitoneal hernia repair (TAPP), which involves fixing transversalis fascia to Cooper ligament, a research investigation has been done.Methods:For direct inguinal hernias, TAPP was incorporated from October 2022 - December 2023. After cavity created by direct reduction of hernia had been closed in each patient by transversalis fascia fixation to coopers, a lightweight mesh was inserted. Data from clinical as well as demographic studies have been obtained as well as examined.Results: A total of 72 individuals that had TAPP repair during study period. Mean age of patients, who were all male, was 65.1 ± 10.7 yrs. Average hospital stay lasted between two and four days. Neither seroma nor recurrence was discovered 30 days after discharge, nor was chronic pain after 3–12 months mean follow-up.Conclusions: To avoid postoperative seromas, it is safe, practical, and advised to anchor transversalis fascia to Cooper ligament while treating a direct inguinal hernia with TAPP

Recommended Articles
Loading Image...
Volume-6, Issue-1
Citations
770 Views
362 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved